EMS-CHEMIE HOLDING AG

BATS-CHIXE:EMSNZ Stock Report

Market Cap: CHF 12.8b

EMS-CHEMIE HOLDING Valuation

Is EMSNZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EMSNZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CHF 547.31
Fair Value
0.4% overvalued intrinsic discount
6
Number of Analysts

Below Fair Value: EMSNZ (CHF549.5) is trading above our estimate of fair value (CHF547.31)

Significantly Below Fair Value: EMSNZ is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EMSNZ?

Key metric: As EMSNZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EMSNZ. This is calculated by dividing EMSNZ's market cap by their current earnings.
What is EMSNZ's PE Ratio?
PE Ratio27.8x
EarningsCHF 461.84m
Market CapCHF 12.82b

Price to Earnings Ratio vs Peers

How does EMSNZ's PE Ratio compare to its peers?

The above table shows the PE ratio for EMSNZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.4x
CRDA Croda International
27.2x16.49%UK£3.8b
VCT Victrex
18.5x20.35%UK£549.7m
TET Treatt
11.4x-6.55%UK£128.4m
FRES Fresnillo
56.4x34.67%UK£19.4b
EMSNZ EMS-CHEMIE HOLDING
27.8x3.80%CHF 12.8b

Price-To-Earnings vs Peers: EMSNZ is good value based on its Price-To-Earnings Ratio (27.8x) compared to the peer average (28.4x).

Price to Earnings Ratio vs Industry

How does EMSNZ's PE Ratio compare vs other companies in the European Chemicals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies14PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EMSNZ is expensive based on its Price-To-Earnings Ratio (27.8x) compared to the European Chemicals industry average (17.6x).

Price to Earnings Ratio vs Fair Ratio

What is EMSNZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EMSNZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.8x
Fair PE Ratio18.8x

Price-To-Earnings vs Fair Ratio: EMSNZ is expensive based on its Price-To-Earnings Ratio (27.8x) compared to the estimated Fair Price-To-Earnings Ratio (18.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EMSNZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 549.50
CHF 667.17
+21.41%
12.46%CHF 750.00CHF 510.00n/a6
Nov ’26CHF 551.50
CHF 667.17
+20.97%
12.46%CHF 750.00CHF 510.00n/a6
Oct ’26CHF 563.50
CHF 671.50
+19.17%
13.00%CHF 750.00CHF 491.00n/a6
Sep ’26CHF 609.50
CHF 660.57
+8.38%
12.89%CHF 750.00CHF 491.00n/a7
Aug ’26CHF 642.50
CHF 660.71
+2.83%
12.89%CHF 750.00CHF 491.00n/a7
Jul ’26CHF 600.50
CHF 663.13
+10.43%
12.20%CHF 750.00CHF 491.00n/a8
Jun ’26CHF 623.50
CHF 663.13
+6.36%
12.20%CHF 750.00CHF 491.00n/a8
May ’26CHF 606.50
CHF 687.25
+13.31%
8.15%CHF 750.00CHF 595.00n/a8
Apr ’26CHF 604.50
CHF 687.38
+13.71%
8.13%CHF 750.00CHF 595.00n/a8
Mar ’26CHF 629.50
CHF 688.00
+9.29%
7.98%CHF 750.00CHF 600.00n/a8
Feb ’26CHF 645.50
CHF 709.57
+9.93%
9.67%CHF 800.00CHF 634.00n/a7
Jan ’26CHF 609.50
CHF 709.57
+16.42%
9.67%CHF 800.00CHF 634.00n/a7
Dec ’25CHF 624.00
CHF 712.86
+14.24%
9.17%CHF 800.00CHF 650.00n/a7
Nov ’25CHF 675.50
CHF 735.71
+8.91%
11.73%CHF 900.00CHF 650.00CHF 551.507
Oct ’25CHF 706.50
CHF 730.63
+3.41%
11.42%CHF 900.00CHF 633.00CHF 563.508
Sep ’25CHF 709.50
CHF 730.63
+2.98%
11.42%CHF 900.00CHF 633.00CHF 609.508
Aug ’25CHF 734.50
CHF 730.63
-0.53%
11.42%CHF 900.00CHF 633.00CHF 642.508
Jul ’25CHF 737.25
CHF 675.00
-8.44%
10.50%CHF 800.00CHF 580.00CHF 600.507
Jun ’25CHF 740.50
CHF 667.14
-9.91%
9.64%CHF 800.00CHF 580.00CHF 623.507
May ’25CHF 737.00
CHF 664.29
-9.87%
9.81%CHF 800.00CHF 580.00CHF 606.507
Apr ’25CHF 692.00
CHF 664.29
-4.00%
9.81%CHF 800.00CHF 580.00CHF 604.507
Mar ’25CHF 623.00
CHF 655.71
+5.25%
12.16%CHF 800.00CHF 547.00CHF 629.507
Feb ’25CHF 656.50
CHF 657.14
+0.098%
12.51%CHF 800.00CHF 547.00CHF 645.507
Jan ’25CHF 679.50
CHF 657.14
-3.29%
12.51%CHF 800.00CHF 547.00CHF 609.507
Dec ’24CHF 619.50
CHF 657.14
+6.08%
12.51%CHF 800.00CHF 547.00CHF 624.007
Nov ’24CHF 623.00
CHF 704.57
+13.09%
11.37%CHF 850.00CHF 613.00CHF 675.507
CHF 668.99
Fair Value
17.9% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/30 14:54
End of Day Share Price 2025/11/28 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

EMS-CHEMIE HOLDING AG is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantin WiechertBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Sebastian BrayBerenberg